eligibility_summary
Adults (≥18) with untreated FL 1–3A or any MZL meeting modified GELF criteria, ECOG 0–2, adequate labs/organ function, consent, contraception, and tumor tissue (fresh or archival). Exclude urgent cytoreduction, immunosuppression (>10 mg prednisone), bulky cervical nodes risking airway, severe mAb allergy, recent major surgery, uncontrolled infection/HIV, active or viremia HBV/HCV, recent major cardiac events, NYHA III/IV HF, pregnancy, prior solid organ/allo SCT, HLH, active autoimmune disease (remote/controlled per PI).
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions: Glofitamab and obinutuzumab, both IV immunotherapies. Glofitamab is a CD20×CD3 T‑cell–engaging bispecific humanized monoclonal antibody that binds CD20 on B cells and CD3 on T cells, redirecting and activating T cells to kill CD20+ lymphoma cells (perforin/granzyme cytotoxicity). Obinutuzumab is a humanized, glycoengineered type II anti‑CD20 monoclonal antibody that induces direct B‑cell death and enhances antibody‑dependent cellular cytotoxicity/phagocytosis. Targets: CD20+ malignant B cells in follicular lymphoma and marginal zone lymphoma and CD3+ T cells to drive anti‑tumor immunity. Phase 2, single‑arm, first‑line study in untreated FL/MZL.